The foregoing measure as well as the continued restriction on the importation of foreign plasma based products have placed pressure on the already tightened supply of plasma available for production. In addition, the overall effect of these and other regulations has been to reduce competition and increase the barriers to entry. In order to maintain its favorable position in the industry, the Company is focusing on its research and development efforts on securing plasma supply and on the development and production of new high quality plasma-based products.
"We are pleased with our operational results given the government's
restriction on both the supply of human plasma and the slow approval
process of the plasma-based products for sale earlier in the year,"
remarked Mr. Zhao. "Now that the government approval process for plasma
based finished goods has returned to more normal levels, we are optimistic
about our outlook for the remainder of the year. We have made great efforts
to secure raw material inventories and finished products in order to better
serve our customers."
CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES
FOR THE THREE MONTHS AND SIX MONTHS ENDED JUNE 30, 2008 AND 2007
Three Months Ended Three Months Ended
Adjusted Net Income June 30, 2008 June 30, 2007
Net Income (Loss) Diluted EPS Net Income EPS Net Income EPS
Adjusted Amount - Non GAAP $3,297,342 $0.15 $3,443,500 $0.16
Non-cash employee compensation (1) $1,263,188 $0.06 -- --
Amount per consolidated statement $2,034,154 $0.09 $3,443,500 $0.16
|SOURCE China Biologic Products, Inc.|
Copyright©2008 PR Newswire.
All rights reserved